Research programme: coronavirus vaccines - VBI Vaccines/National Research Council of Canada
Alternative Names: Coronavirus X vaccines-VBI Vaccines/National Research Council of Canada; VBI-2900Latest Information Update: 28 Sep 2024
At a glance
- Originator National Research Council Canada; VBI Vaccines
- Class COVID-19 vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Canada
- 28 Feb 2023 VBI Vaccine signed a seventh amendment to the collaboration agreement with the National Research Council of Canada to extend the expiration date of the collaboration agreement until December 31, 2023
- 07 Dec 2022 VBI Vaccines and the Coalition for Epidemic Preparedness Innovations expands its collaboration to co-develop VBI’s eVLP furture vaccine candidates for COVID-2019 infections (Prevention)